STOCK TITAN

Mark Bunnage sells VRTX shares; multiple trades reported (VRTX)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Mark E. Bunnage reported sales of common stock under Rule 144. The filing lists four dispositions: 12/29/202523 shares for $10,649.00; 02/11/20262,021 shares for $930,529.03; 02/17/20262,437 shares for $1,192,814.02; and 02/18/20261,182 shares for $559,889.76. The transactions are reported as sales by the holder and include a separate 620-share restricted stock vesting on 02/24/2026 noted as compensation.

Positive

  • None.

Negative

  • None.

Insights

Insider sales of common stock were reported across four trades in late 2025 and February 2026.

The filing documents specific dispositions by Mark E. Bunnage with per-trade counts and dollar amounts, consistent with Rule 144 reporting for restricted or control-person sales. These are ordinary filings that disclose transaction details.

Impact appears routine; subsequent filings may clarify whether sales were pre-arranged or routine portfolio actions.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What transactions did Mark E. Bunnage report in the Rule 144 filing for VRTX?

He reported four sales and one vesting event. The filing lists sales on 12/29/2025, 02/11/2026, 02/17/2026, and 02/18/2026, plus a 620-share restricted stock vesting on 02/24/2026 labeled as compensation.

How many shares and proceeds are shown for each reported sale?

Each sale is listed with quantity and dollar proceeds. The filing shows 23 shares for $10,649.00; 2,021 for $930,529.03; 2,437 for $1,192,814.02; 1,182 for $559,889.76.

Does the filing indicate whether the sales were open-market or part of a plan for VRTX?

The excerpt lists transaction types but not execution method. It reports dispositions with dates and amounts; the filing text does not specify whether trades were open-market, pursuant to a 10b5-1 plan, or otherwise.

Is there any indication of proceeds received by the issuer in this filing?

No issuer proceeds are reported in these transactions. The entries show sales by the holder and a restricted stock vesting described as compensation; the filing does not state that the issuer received sale proceeds.

What is the significance of the 620-share entry dated 02/24/2026?

That entry records restricted stock vesting as compensation. The filing shows a 620-share Common stock item on 02/24/2026 identified as "Restricted Stock Vesting" and categorized as compensation.
Vertex Pharmaceuticals Inc

NASDAQ:VRTX

VRTX Rankings

VRTX Latest News

VRTX Latest SEC Filings

VRTX Stock Data

122.71B
253.45M
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON